

**Systematic review of the evidence for a relationship between docosahexaenoic acid (DHA) and maintenance of normal brain function and normal vision**

**Prepared by: Food Standards Australia New Zealand**

**Date: October 2015**

#

**Executive Summary**

|  |
| --- |
| ***Is dietary intake of docosahexaenoic acid (DHA) required to maintain normal brain function?*** |
| **Food health relationship** | Dietary intake of DHA is required to maintain normal brain function |
| **Proposed degree of certainty (GRADE rating)** | Non-assessable  |
| **Component** | **Notes**  |
| ***Body of evidence*** | No suitable human case reports, case series or clinical trials examining the effects of deficiency of dietary DHA were identified and, therefore, none were included in this systematic review.  |
| ***Consistency*** | There was no body of evidence to assess for consistency. |
| ***Causality*** | There was no body of evidence to assess from which to draw a conclusion about causality.  |
| ***Plausibility*** | It is plausible that dietary deficiency of the lipid could influence normal brain function, as DHA is a major fatty acid component of the human brain. However DHA is formed in the body from polyunsaturated fatty acids, most notably alpha-linolenic acid. |
| ***Generalisability*** | No suitable studies could be identified in humans. Generalisability to food or property of food for consumption by healthy individuals is not applicable. |

|  |
| --- |
| ***Is dietary intake of docosahexaenoic acid (DHA) required to maintain normal vision?*** |
| **Food health relationship** | Dietary intake of DHA is required to maintain normal vision |
| **Proposed degree of certainty (GRADE rating)** | Non-assessable |
| **Component** | **Notes**  |
| ***Body of evidence*** | No suitable human case reports, case series or clinical trials examining the effects of deficiency of dietary DHA were identified and, therefore, none were included in this systematic review.  |
| ***Consistency*** | There was no body of evidence to assess for consistency. |
| ***Causality*** | There was no body of evidence to assess from which to draw a conclusion about causality. |
| ***Plausibility*** | It is plausible that dietary deficiency of the lipid could influence normal vision, as DHA is a major fatty acid component of the human retina. However DHA is formed in the body from polyunsaturated fatty acids, most notably alpha-linolenic acid. |
| ***Generalisability*** | No suitable studies could be identified in humans. Generalisability to food or property of food for consumption by healthy individuals is not applicable. |

FSANZ has conducted a systematic review on dietary deficiency of DHA and the maintenance of normal brain and vision functions. In doing this review, FSANZ has followed the requirements of the *Application Handbook* and of Schedule 6 of Standard 1.2.7 – Nutrition, Health and Related Claims, for the required elements of a systematic review.

FSANZ identified five case studies in which seriously ill patients received DHA. However, none of these studies assessed any aspect of brain or vision functions after the intervention.

Due to the lack of suitable human studies of DHA and maintenance of normal brain and vision functions, FSANZ regards the two relationships that are the subject of this review as being ‘non-assessable’.

**Contents**

[1 Introduction 1](#_Toc446325768)

[1.1 Food or the property of food 1](#_Toc446325769)

[1.2 Health effect 2](#_Toc446325770)

[1.3 Proposed relationships 2](#_Toc446325771)

[2 Evaluation of evidence 3](#_Toc446325772)

[2.1 Methods 3](#_Toc446325773)

[2.1.1 Search strategy 3](#_Toc446325774)

[2.1.2 Inclusion and exclusion criteria 3](#_Toc446325775)

[2.1.3 Study selection, data extraction and quality assessment 4](#_Toc446325776)

[2.1.4 Statistical analyses 5](#_Toc446325777)

[2.1.5 Subgroup analyses 5](#_Toc446325778)

[2.2 Results 5](#_Toc446325779)

[2.2.1 Search results 5](#_Toc446325780)

[2.2.2 Included studies 5](#_Toc446325781)

[2.2.3 Quality assessment of studies 5](#_Toc446325782)

[2.3 Summary of evidence 6](#_Toc446325783)

[2.3.1 DHA and normal brain function 6](#_Toc446325784)

[2.3.2 DHA and normal vision 7](#_Toc446325785)

[3 Weight of evidence 7](#_Toc446325786)

[3.1 Assessment of body of evidence 7](#_Toc446325787)

[3.1.1 Consistency of relationship 7](#_Toc446325788)

[3.1.2 Causality 7](#_Toc446325789)

[3.1.3 Plausibility 7](#_Toc446325790)

[3.2 Applicability to Australia and New Zealand 8](#_Toc446325791)

[3.2.1 Intake required for effect 8](#_Toc446325792)

[3.2.2 Target population 8](#_Toc446325793)

[3.2.3 Extrapolation from supplements 8](#_Toc446325794)

[3.2.4 Adverse effects 8](#_Toc446325795)

[4 Conclusion 8](#_Toc446325796)

[5 References 8](#_Toc446325797)

[Appendix 1: Search terms 17](#_Toc446325798)

[Appendix 2: Studies excluded at full text review 18](#_Toc446325799)

[Appendix 3: GRADE summary of findings tables 25](#_Toc446325800)

# Introduction

In 2012, the European Union (EU) authorised (Commission Regulation (EU) No. 432/2012) two health claims about the relationship between docosahexaenoic acid (DHA) and its contribution to the maintenance of normal brain function and normal vision. FSANZ notes that the condition associated with both claims was that “the claim may be used only for food which contains at least 40 mg of DHA per 100 g and per 100 kcal. In order to bear the claim, information shall be given to the consumer that the beneficial effect is obtained with a daily intake of 250 mg of DHA”.

In examining the evidence to support both these claims, the European Food Safety Authority (EFSA) noted that DHA is a major structural lipid in the human brain and retina (EFSA Panel on Dietetic Products 2010). They also cited the United States Institute of Medicine’s (IoM) 2005 review of dietary requirements for lipids (IoM 2005). The IoM review concluded that alpha-linolenic acid (ALA), i.e. the precursor fatty acid for omega-3 long-chain (≥ C20) polyunsaturated fatty acids (n-3 LC-PUFAs) such as DHA, is an essential nutrient. While recommending a dietary intake of ALA, the IoM did not recommend that the dietary intake of DHA is essential.

FSANZ notes that neither EFSA nor IoM carried out systematic reviews of the literature to examine the relationships between consumption of DHA and the maintenance of normal brain function and vision. FSANZ also noted that EFSA made its recommendations based on the IoM report (IoM 2005) by considering the adverse clinical symptoms of ALA deficiency as the evidence for DHA, the end-product of ALA endogenous conversion, in maintaining normal both brain function and vision. EFSA has also considered other evidence for the structural and biochemical role of DHA in the human brain and neural tissue in the eye to support the claims. However, EFSA did not consider the evidence for the relationship of dietary intake of DHA and the contribution to the maintenance of normal brain function and normal vision (EFSA Panel on Dietetic Products 2010).

FSANZ is considering whether a relationship between DHA and the maintenance of normal brain function and normal vision can be incorporated into Schedule 3 of Standard 1.2.7 – Nutrition, Health and Related Claims. FSANZ considers that ‘contributes to the maintenance’ is part of the wording specifications for the EU claim. Therefore, the relationships to be investigated by FSANZ are that dietary intake of DHA is required to maintain normal brain and that dietary intake of DHA is required to maintain normal vision. The purpose of this paper is to systematically review the evidence for these relationships.

## Food or the property of food

DHA is a well-characterised n-3 LC-PUFA containing 22 carbon atoms and six *cis* unsaturated bonds (i.e. double bonds), the first of which is at the third carbon atom counting from the omega end of the carbon chain. DHA is abundant in marine oils and oily marine fish (e.g. mackerel, tuna, salmon, sardines and herring). DHA rarely exists as a free fatty acid in food and usually occurs in the triglyceride form, with lesser amounts present in a phospholipid form (Haraldsson and Hjaltason 2001; Srigley and Rader 2014). Humans can biosynthesise only small amounts of n-3 LC-PUFA from precursors, such as ALA, which is available from vegetable oils (Goyens et al. 2006; Brenna et al. 2009). Food sources rich in DHA are few, especially since terrestrial edible plants cannot make this fatty acid. Most human populations receive their dietary DHA directly from the seafood they consume or through maternal nutrition (i.e. breastfeeding) for infants. Natural accumulation of DHA occurs throughout the marine food web, starting mainly from algae and lower fungi that are capable of synthesising DHA. Small crustaceans and forage fish feed on algae and lower fungi to obtain nutrients including DHA that accumulate in larger amounts in the tissues of predatory fish (Bell and Tocher 2009; Gladyshev et al. 2013). In line with that fact, the main food source of DHA for Australians and New Zealanders is seafood and marine oils (Meyer et al. 2003; NHMRC 2005; University of Otago and Ministry of Health 2011; Australia Bureau of Statistics 2014).

After extraction with an organic solvent and conversion to the corresponding methyl ester, DHA content in food and blood serum or plasma is mainly measured by gas chromatography (GC) with flame ionization detection (GC-FID) and, when necessary, with mass spectrometric detection (MS) (Christie 1998; AOAC 2000).

For the purpose of these food-health relationships, only DHA as a fatty acid in triglyceride, phospholipid or other lipid forms is considered. Oil mixtures rich in DHA such as fish oil and other n-3 LC-PUFA such as eicosapentaenoic acid (EPA) or docosapentaenoic acid (DPA) are not the subject of this of this systematic review.

## Health effect

The abovementioned EU claims are non-specific in describing what aspects of normal brain or vision functions the claims relate to. Therefore, FSANZ used a broad definition of the health effects in the systematic review.

Brain function could include any aspect of cognitive, behavioural, psychological or neural brain functions. Cognitive, behavioural and psychological functions are assessed mainly by psychometric testing, such as computerised batteries of tests (tasks and cognitive skills), the Bayley Scales and normative scores like intelligence quotient (IQ) amongst few other methods (Ryan and Nelson 2008; Politi et al. 2008; Kennedy et al. 2009; Sun et al. 2015). Neural brain functions are frequently assessed, amongst many other valid techniques, by biochemical, molecular and imagining techniques as well as neurodegenerative and neuromotor activity assessments such as Alzheimer’s Disease Assessment Scale (Martinez and Vazquez 1998; Wurtman et al. 2009; Quinn et al. 2010; Bauer et al. 2014). These methods of assessment have been widely used, standardised and referenced in scientific articles related to brain functions.

The definition of vision could include visual acuity, macular health and retinal neural activity. Visual acuity is usually assessed by standardised measurements employing numerical or graphical charts, such as Snellen chart, electrophysiology and electroretinography utilising contact lens electrodes (Uauy et al. 1990; Birch et al. 2010; Berson et al. 2012). Retinal activity, macular degeneration, maculopathy and optical density of macular pigment are also assessed frequently by several standardised methods such as fundus and photographic grading, retinal pigmentation and drusen diagnosis (Chong et al. 2008; Kishan et al. 2011; Stough et al. 2012). These standard methods can assess and quantify vision functions effectively and have been widely used and cited in scientific literature related to vision function.

## Proposed relationships

The food-health relationships being assessed in this report are:

* Dietary intake of DHA is required to maintain normal brain function.
* Dietary intake of DHA is required to maintain normal vision.

# Evaluation of evidence

The relationship investigated by FSANZ was that dietary intake of DHA is required to maintain normal brain function and/or normal vision, rather than increased DHA intake enhancing these functions. Therefore FSANZ has examined the evidence for dietary deficiency of DHA.

FSANZ could not identify an existing systematic review of DHA-deficient diets in humans and development of clinical symptoms related to brain function or vision that were reversed by the administration of DHA. Therefore, a new systematic review was undertaken.

## Methods

### Search strategy

Owing to the scarcity of data and because some relevant articles refer to ALA or LA, a broad electronic database search strategy was designed to retrieve publications about the effects of essential fatty acids on general health and physiological functions in humans. The aim of the search was to identify all health outcomes associated with diets deficient in DHA. Therefore, no specific outcome measures were included in the search.

Searches were conducted in EMBASE, PubMed and Cochrane CENTRAL between the 3rd and the 10th of March 2015. Detailed search strategies are presented in Appendix 1. In EMBASE and PubMed, Medical Subject Headings (MeSH) terms were used to refine the scope of the search results. PubMed results were limited to studies in humans. No date limits were applied to any searches. Additional references were also identified by hand-searching the reference lists of studies assessed at the full-text stage of screening.

The Australia New Zealand and WHO Clinical Trials Registries were searched on 28 July 2015 for ‘essential fatty acid’. Only one study (ACTRN12610000616077, from 2010, retrospectively registered) was identified as being potentially relevant to this review. A paper that appears to be the result of that study (Bauer et al. 2014) was located. However, the paper was identified as a review article. Other identified registered trials did not include DHA as the intervention, did not examine the effects of deficiency, or did not examine the maintenance of normal functions.

To check the validity of the literature search strategy, FSANZ examined the reference lists cited by the EFSA opinion (EFSA Panel on Dietetic Products 2010), the National Health and Medical Research Council and New Zealand Ministry of Health (NHMRC and NZ MoH, 2006) and the US Institute of Medicine (IoM 2005). All relevant studies cited in these reports were contained in the literature retrieved using the search strategy shown in Appendix 1. Therefore FSANZ believes that no relevant literature has been missed.

### Inclusion and exclusion criteria

Studies to be included were not limited to a particular study design, as relevant information may have been found in case reports, case series, randomised trials or some other designs. Study subjects and participants could be adults or children 12 months of age and older. No exclusion criteria were set based on the health of subjects or participants. The eligibility criteria are summarised in Table 1. DHA intervention could be given in various ways, such as an oil emulsion added to parenteral or enteral feeding, or a specific fatty acid ester. To be included, studies must have included both a lipid-free (or negligible lipid) phase and a phase where DHA was added to the baseline diet. Studies using mixtures of fatty acids that included DHA as the intervention and compared with a control treatment receiving the same mixture of fatty acid but lacking DHA were included as the difference in the assessed effect on brain or vision functions was likely attributed to the intervention with DHA. Therefore studies in which symptoms of lipid deficiency were reported but no lipid was administered to treat these symptoms were excluded.

To be included, studies must have provided information on clinical changes in participants. Studies where the only reported changes were in biochemical parameters, such as plasma levels of fatty acids and/or DHA, were excluded. While many authors regard the appearance in plasma of the 20:3 n-9 (mead acid) or an elevated ratio of that fatty acid to that of 20:4 n-6 (arachidonic acid), as being diagnostic of fatty acid deficiency, there does not appear to be a consensus on the diagnostic value of this ratio and, therefore, only clinical criteria were used as the outcome. However, where included studies reported one or both of these parameters, this information was recorded. No minimum study duration was set.

*Table 1 PICOTS criteria for study selection*

|  |  |
| --- | --- |
| **Population** | Participants 12 months of age and older maintained on DHA-free or extremely low DHA diets or nutrition support regimens with participants experiencing clinical signs or symptoms before intervention. |
| **Intervention** | DHA source added to nutrition support, including oils or as pure fatty acid esters. |
| **Comparator** | For case studies, comparator is the same individual before DHA intervention was initiated. For trials, comparator is participants who either continued on a DHA-free diet or received other fatty acid mixtures lacking DHA. |
| **Outcome** | All reported clinical and behavioural signs or symptoms related to brain and vision functions. |
| **Time** | No limits. |
| **Study design** | Randomised controlled trials, clinical trials, case series or case reports. |

**Exclusion criteria**

The following exclusion criteria were established:

* Studies where the outcome was changes in plasma or serum lipid profile, without accompanying clinical signs or symptoms
* Patients who were given multiple concurrent dietary interventions, including EPA or other fatty acids
* Patients who did not have clinical signs or symptoms of deficiency before DHA intervention was initiated.
* Diets that contained substantial lipid or DHA intake before the intervention, for example from concurrent food consumption
* Studies involving enhanced intake, i.e. above the normal dietary intakes in healthy populations.

### Study selection, data extraction and quality assessment

Records identified during the search process were imported into EPPI-Reviewer 4 (http://eppi.ioe.ac.uk/cms/er4). Following removal of duplicates, records were screened on title and abstract. Candidate full-text articles were retrieved and assessed against the inclusion/exclusion criteria. Screening was conducted by two investigators.

As no studies were found, no data extraction or quality assessment was done of individual studies (Higgins and Green 2011) or the body of evidence (Guyatt et al. 2011).

### Statistical analyses

Neither meta-analysis nor another type of statistical analysis was undertaken as there were no included studies with data to extract and compare.

### Subgroup analyses

No sub-group analysis has been carried out due to the lack of studies and populations to compare.

## Results

### Search results

The screening of articles retrieved from the search strategies is detailed in Figure 1. Studies excluded after full text examination are listed in Appendix 2. No studies were included.

### Included studies

There were 98 studies screened on full text but they were all excluded for not meeting one or more of the PICOTS criteria. Of the 98 studies screened on full text, there were five studies (Bjerve et al. 1987a; Bjerve et al. 1988; Bjerve 1989; Bjerve et al. 1989; Gura et al. 2005) administering DHA as an intervention but within a mixture of other fatty acids, without an appropriate comparator and without assessing any aspect of brain or vision function. Therefore, no studies meeting the PICOTS criteria were found in this systematic review to be included for further assessment.

### Quality assessment of studies

As there were no studies that met the inclusion criteria in this systematic review, no individual or overall quality assessment of studies was performed. Similarly, publication bias could not be assessed in this review.

1807 articles identified through database searches

1556 articles screened on title/abstract

269 duplicates removed

98 articles screened on full text

1458 excluded on title/abstract

0 articles included

98 Exclusions:

* 19, Clinical symptoms not reported
* 14, No dietary intervention with lipid
* 12, Reviews or letters to editor
* 7, Lipids not sole intervention
* 5, Unable to locate or translate
* 3, Background diet not lipid free
* 33, No DHA intervention
* 5, Brain or vision functions not assessed after DHA intervention.

18 articles identified through hand-searching

**Figure 1.** PRISMA diagram of study identification process

## Summary of evidence

### DHA and normal brain function

There were no studies identified that used DHA as the intervention followed by the assessment of any aspect of brain functions following the intervention. Therefore, there is no evidence to be assessed.

### DHA and normal vision

There were no studies identified that used DHA as the intervention followed by the assessment of change in vision following the intervention. Therefore, there is no evidence to be assessed.

# Weight of evidence

This systematic review aimed to identify all available human studies examining the contribution of DHA, as food or a property of food, in the maintenance of normal brain function and normal vision and whether clinical symptoms of compromised normal brain function and normal vision subsequently improved or resolved with the consumption of DHA.

To ensure that all studies might be captured, a broad search strategy was designed. Of the 98 articles screened on full text, no studies were identified that met the inclusion criteria. Some case reports of seriously ill patients used Intralipid® (emulsion of soy bean oil, egg phospholipids and glycerine) parenteral intervention that did not contain DHA and some other case reports of other seriously ill patients used DHA as the intervention but did not assess brain or vision functions. Therefore, no evidence derived from human studies was identified that could be used to establish a relationship between dietary DHA and maintenance of normal brain function or normal vision.

For a food-health relationship to be substantiated there has to be a consistent effect across high quality studies. No high quality studies, or, indeed, low quality studies, were identified in this review. Thus, as there is no available evidence, FSANZ concludes the relationships between DHA and normal brain function or between DHA and normal vision are both non-assessable.

FSANZ notes that there are some studies in infants, who are under the age of 12 months as defined in Standard 2.9.1 of the *Australia New Zealand Food Standards Code*, that examined brain and vision functions following feeding of DHA-rich formula. However, as health claims are not allowed on infant formula product within the current regulatory framework, these studies were not within the scope of this systematic review and their outcomes cannot be extrapolated to adults. Furthermore, FSANZ is also aware that there are a considerable number of human studies examining the effects of *enhanced* intake of n-3 LC-PUFA on selected aspects of brain or vision functions, or in the treatment of neurological or psychiatric conditions, rather than the *maintenance* of normal brain or normal vision functions.

## Assessment of body of evidence

### Consistency of relationship

Not assessed due to the absence of evidence.

### Causality

Not assessed due to the absence of evidence.

### Plausibility

DHA serves as a key component in neurotransmission and cell membrane structure in the brain and retina (Salem, Jr. et al. 2001; Rapoport et al. 2011). Therefore it is plausible that intake of DHA could affect the function of these organs as well. However, DHA can be formed in the body from its precursors which are other n-3 polyunsaturated fatty acids such as ALA, which is found in terrestrial vegetable oils. Other n-3 LC-PUFA such as EPA or DPA can also be endogenously converted into DHA (Bjerve 1989; Brenna et al. 2009). The properties of DHA have been shown to include effects on cerebral and retinal neuronal development and plasticity, receptor-mediated signalling, changes in membrane fluidity, the formation of second messengers, and/or enhancement of the production of anti-inflammatory lipid mediators due to the availability of DHA as a substrate (Salem, Jr. et al. 2001; SanGiovanni and Chew 2005; Bazan 2005).

## Applicability to Australia and New Zealand

### Intake required for effect

Not assessed due to the absence of evidence.

### Target population

Not assessed due to the absence of evidence.

### Extrapolation from supplements

Not assessed due to the absence of evidence.

### Adverse effects

Not assessed due to the absence of evidence.

# Conclusion

Due to the lack of evidence, FSANZ considers that relationships between dietary DHA intake and the maintenance of normal brain function or dietary DHA intake and the maintenance of normal vision, are non-assessable.

# References

Anon (1959) Essential fatty acid deficiency in infants. Nutr Rev 17(5):136–138

Anon (1985) Development of essential fatty acid deficiency in the premature infant given fat-free TPN. Nutr Rev 43(1):14–15

Anon (1986) Combined EFA deficiency in a patient on long-term TPN. Nutr Rev 44(9):301–305

AOAC (2000) AOAC official method 963.22. Methyl esters of fatty acids in oils and fats. In: Official Methods of Analysis of the AOAC. 17th ed, Arlington,

Australia Bureau of Statistics (2014) Australian Health Survey: Nutrition First Results-Foods and Nutrients, 2011-12.

[http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/by%20Subject/4364.0.55.007~2011-12~Main%20Features~Key%20Findings~1](http://www.abs.gov.au/ausstats/abs%40.nsf/Lookup/by%20Subject/4364.0.55.007~2011-12~Main%20Features~Key%20Findings~1). Accessed 13 March 2015

Ballabriga A, Martinez M (1976) Changes in erythrocyte lipid stroma in the premature infant according to dietary fat composition. Acta Paediatr Scand 65(6):705–709

Barr LH, Dunn GD, Brennan MF (1981) Essential fatty acid deficiency during total parenteral nutrition. Ann Surg 193(3):304–311

Bauer I, Hughes M, Rowsell R, Cockerell R, Pipingas A, Crewther S, Crewther D (2014) Omega-3 supplementation improves cognition and modifies brain activation in young adults. Hum Psychopharmacol 29(2):133–144

Bazan NG (2005) Lipid signaling in neural plasticity, brain repair, and neuroprotection. Mol Neurobiol 32(1):89–103

Bell M, Tocher D (2009) Biosynthesis of polyunsaturated fatty acids in aquatic ecosystems: general pathways and new directions. In: Kainz M, Brett MT, and Arts MT (eds) Lipids in Aquatic Ecosystems. Springer New York, p. 211–236

Berg G, Sailer D, Heid H (1976) Essentielles Fettsäuremangel-Syndrom beim Menschen. Z Ernährungswiss 15(1):39–51

Berson EL, Rosner B, Sandberg MA, Weigel-DiFranco C, Willett WC (2012) ω-3 intake and visual acuity in patients with retinitis pigmentosa receiving vitamin A. Arch Ophthalmol 130(6):707–711

Birch EE, Carlson SE, Hoffman DR, Fitzgerald-Gustafson KM, Fu VL, Drover JR, Castaneda YS, Minns L, Wheaton DK, Mundy D, Marunycz J, Diersen-Schade DA (2010) The DIAMOND (DHA Intake And Measurement Of Neural Development) study: a double-masked, randomized controlled clinical trial of the maturation of infant visual acuity as a function of the dietary level of docosahexaenoic acid. Am J Clin Nutr 91(4):848–859

Bistrian BR, Bothe A, Jr., Blackburn GL, DeFriez AI (1981) Low plasma cortisol and hematologic abnormalities associated with essential fatty acid deficiency in man. J Parenter Enteral Nutr 5(2):141–144

Bjerve KS (1985) Essential fatty acid deficiency in long-term peroral tubal feeding. Tidsskr Nor Laegeforen 105(31):2242

Bjerve KS (1989) n-3 fatty acid deficiency in man. J Intern Med Suppl 731:171–175

Bjerve KS, Thoresen L, Christiansen EN (1986) Essential linolenic fatty acid deficiency. Patients on long-term gastric tube feeding. Tidsskr Nor Laegeforen 106(34-36):2978–2981

Bjerve KS, Mostad IL, Thoresen L (1987a) Alpha-linolenic acid deficiency in patients on long-term gastric-tube feeding: estimation of linolenic acid and long-chain unsaturated n-3 fatty acid requirement in man. Am J Clin Nutr 45(1):66–77

Bjerve KS, Fischer S, Alme K (1987b) Alpha-linolenic acid deficiency in man: effect of ethyl linolenate on plasma and erythrocyte fatty acid composition and biosynthesis of prostanoids. Am J Clin Nutr 46(4):570–576

Bjerve KS, Thoresen L, Borsting S (1988) Linseed and cod liver oil induce rapid growth in a 7-year-old girl with N-3- fatty acid deficiency. JPEN J Parenter Enteral Nutr 12(5):521–525

Bjerve KS, Thoresen L, Mostad IL, Alme K (1987c) Alpha-linolenic acid deficiency in man: effect of essential fatty acids on fatty acid composition. Adv Prostaglandin Thromboxane Leukot Res 17B:862–865

Bjerve KS, Fischer S, Wammer F, Egeland T (1989) a-Linolenic acid and long-chain w-3 fatty acid supplementation in three patients with w-3 fatty acid deficiency: effect on lymphocyte function, plasma and red cell lipids, and prostanoid formation. Am J Clin Nutr 49(2):290–300

Bozian RC, Piepmeyer JL (1976) Fatty acid deficiency. Ann Intern Med 85(4):540–541

Bozian RC, Moussavian SN (1982) Human linolenic acid deficiency. Am J Clin Nutr 36(6):1253–1255

Brenna JT, Salem N, Jr., Sinclair AJ, Cunnane SC (2009) a-Linolenic acid supplementation and conversion to n-3 long-chain polyunsaturated fatty acids in humans. Prostaglandins Leukot Essent Fatty Acids 80(2-3):85–91

Brown WR, Hansen AE, McQuarrie I, Burr GO (1937) Observations on human subject subsisting six months on a diet extremely low in fat. Exp Biol Med 36(3):281–283

Burney DP, Goodwin CD, Caldwell MD, Amoury RA (1979) Essential fatty acid deficiency and impaired wound healing in an infant with gastroschisis. Am Surg 45(8):542

Caldwell MD, Jonsson HT, Othersen HB, Jr. (1972) Essential fatty acid deficiency in an infant receiving prolonged parenteral alimentation. J Pediatr 81(5):894–898

Cederholm TE, Berg AB, Johansson EK, Hellstrom KH, Palmblad JE (1994) Low levels of essential fatty acids are related to impaired delayed skin hypersensitivity in malnourished chronically ill elderly people. Eur J Clin Invest 24(9):615–620

Chase HP, Cotton EK, Elliott RB (1979) Intravenous linoleic acid supplementation in children with cystic fibrosis. Pediatrics 64(2):207–213

Chong EW, Kreis AJ, Wong TY, Simpson JA, Guymer RH (2008) Dietary w-3 fatty acid and fish intake in the primary prevention of age-related macular degeneration: a systematic review and meta-analysis. Arch Ophthalmol 126(6):826–833

Christie WW (1998) Gas chromatography-mass spectrometry methods for structural analysis of fatty acids. Lipids 33(4):343–353

Collins FD, Connelly JF (1965) A fatty acid characteristic of a deficiency of linoleic acid in a case of hepatoma. Lancet 2(7418):883–885

Collins FD, Sinclair AJ, Royle JP, Coats DA, Maynard AT, Leonard RF (1971) Plasma lipids in human linoleic acid deficiency. Nutr Metab 13(3):150–167

Darmstadt GL, McGuire J, Ziboh VA (2000) Malnutrition-associated rash of cystic fibrosis. Pediatr Dermatol 17(5):337–347

de Meijer VE, Gura KM, Meisel JA, Le HD, Puder M (2009) Parenteral fish oil as monotherapy for patients with parenteral nutrition-associated liver disease. Pediatr Surg Int 25(1):123–124

de Meijer VE, Le HD, Meisel JA, Gura KM, Puder M (2010) Parenteral fish oil as monotherapy prevents essential fatty acid deficiency in parenteral nutrition-dependent patients. J Pediatr Gastroenterol Nutr 50(2):212–218

Dodge JA, Salter DG, Yassa JG (1975) Letter: Essential fatty acid deficiency due to artificial diet in cystic fibrosis. Br Med J 2(5964):192–193

Duerksen D, McCurdy K (2005) Essential fatty acid deficiency in a severely malnourished patient receiving parenteral nutrition. Dig Dis Sci 50(12):2386–2388

EFSA Panel on Dietetic Products NaAN (2010) Scientific Opinion on the substantiation of health claims related to docosahexaenoic acid (DHA) and maintenance of normal (fasting) blood concentrations of triglycerides (ID 533, 691, 3150), protection of blood lipids from oxidative damage (ID 630), contribution to the maintenance or achievement of a normal body weight (ID 629), brain, eye and nerve development (ID 627, 689, 704, 742, 3148, 3151), maintenance of normal brain function (ID 565, 626, 631, 689, 690, 704, 742, 3148, 3151), maintenance of normal vision (ID 627, 632, 743, 3149) and maintenance of normal spermatozoa motility (ID 628) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 8(10):1734–1761

Esteve-Comas M, Gassull MA (2001) Abnormal fatty acid status in patients with Crohn disease. Am J Clin Nutr 73(3):661–662

Faintuch J, Machado MC, Bove P, Raia AA (1976) Syndrome of essential fatty acid deficiency in parenteral feeding. Report of 2 cases in adults with characteristic clinical symptoms. Rev Hosp Clin Fac Med Sao Paulo 31(5):414–419

Faintuch J, Machado MC, Bove P, Raia AA (1977) Essential fatty acid deficiency during parenteral hyperalimentation. Int Surg 62(4):243–246

Fleming CR, Smith LM, Hodges RE (1976a) Essential fatty acid deficiency in adults receiving total parenteral nutrition. Am J Clin Nutr 29(9):976–983

Fleming CR, Hodges RE, Smith LM, Hurley LS (1976b) Essential fatty acid, copper, zinc and tocopherol deficiencies in total parenteral nutrition. Acta Chir Scand Suppl 466:20–21

Freund H, Floman N, Schwartz B, Fischer JE (1979) Essential fatty acid deficiency in total parenteral nutrition. Detection by changes in intraocular pressure. Ann Surg 190(2):139–143

Friedman Z, Danon A, Stahlman MT, Oates JA (1976) Rapid onset of essential fatty acid deficiency in the newborn. Pediatrics 58(5):640–649

Gladyshev MI, Sushchik NN, Makhutova ON (2013) Production of EPA and DHA in aquatic ecosystems and their transfer to the land. Prostaglandins Other Lipid Mediat 107:117–126

Goodgame JT, Lowry SF, Brennan MF (1978) Essential fatty acid deficiency in total parenteral nutrition: time course of development and suggestions for therapy. Surgery 84(2):271–277

Goyens PL, Spilker ME, Zock PL, Katan MB, Mensink RP (2006) Conversion of a-linolenic acid in humans is influenced by the absolute amounts of a-linolenic acid and linoleic acid in the diet and not by their ratio. Am J Clin Nutr 84(1):44–53

Gröer Fv (1919) Zur Frage der praktischen Bedeutung des Nährwertbegriffes nebst einigen Bemerkungen über das Fettminimum des menschlichen Säuglings. Biochem Z 97:311

Gura KM, Parsons SK, Bechard LJ, Henderson T, Dorsey M, Phipatanakul W, Duggan C, Puder M, Lenders C (2005) Use of a fish oil-based lipid emulsion to treat essential fatty acid deficiency in a soy allergic patient receiving parenteral nutrition. Clin Nutr 24(5):839–847

Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A (2011) GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol 64(4):380–382

Hansen AE, Wiese HF (1954) Essential fatty acids and human nutrition. II. Serum level for unsaturated fatty acids in poorly-nourished infants and children. J Nutr 52(3):367–374

Hansen AE, Haggard ME, Boelsche AN, Adam DJ, Wiese HF (1958) Essential fatty acids in infant nutrition. III. Clinical manifestations of linoleic acid deficiency. J Nutr 66(4):565–576

Hansen, AE, Wiese, HF, Boelsche, AN, Haggard, ME, Adam, DTD, and Davis, H (1963) Role of linoleic acid in infant nutrition. Clinical and chemical study of 428 infants fed on milk mixtures varying in kind and amount of fat. Pediatrics 31, p. 171-192

Haraldsson GG, Hjaltason B (2001) Fish oils as sources of important polyunsaturated fatty acids. In: Gunstone F (ed) Structured and Modified Lipids. Dekker: New York, p. 313–350

Heymans HS, van den Heuvel CG, Smit W, Steendijk R (1982) Catch-up growth following long-term administration of essential fatty acids in a girl with growth failure and essential fatty acid deficiency. Acta Paediatr Scand 71(6):1037–1039

Higgins JPT, Green S (2011) Cochrane Handbook for Systematic Reviews of Interventions. Higgins, J. P. T. and Green, S. (eds) Cochrane Collaboration,

Hirono H, Suzuki H, Igarashi Y, Konno T (1977) Essential fatty acid deficiency induced by total parenteral nutrition and by medium-chain triglyceride feeding. Am J Clin Nutr 30(10):1670–1676

Holman RT, Johnson SB, Hatch TF (1982) A case of human linolenic acid deficiency involving neurological abnormalities. Am J Clin Nutr 35(3):617–623

Hurgoiu V, Ciupe R, Adam M, Marcu A (1986) Optimization of nutrition for premature infants using essential fatty acids. Rev Pediatr Obstet Ginecol Pediatr 35(4):367–370

Igarashi N, Hashimoto H, Hiratani M, Taniguchi M, Kasahara Y, Sato T, Taniguchi N, Funabashi T, Okuda N, Yamashiro Y (1989) Two cases of cystic fibrosis in Japanese children: studies on the essential fatty acid and prostaglandin metabolism. Acta Paediatr Jpn 31(2):205–210

IoM (2005) Dietary fats: Total fat and fatty acids. In: Food & Nutrition Board IoM (ed) National Academic Press, Washington DC, p. 422–541

James AT, Lovelock JE (1958) Essential fatty acids and human disease. Br Med Bull 14(3):262–266

Jeejeebhoy KN, Zohrab WJ, Langer B, Phillips MJ, Kuksis A, Anderson GH (1973) Total parenteral nutrition at home for 23 months, without complication, and with good rehabilitation. A study of technical and metabolic features. Gastroenterology 65(5):811–820

Jeppesen PB, Hoy CE, Mortensen PB (1998) Essential fatty acid deficiency in patients receiving home parenteral nutrition. Am J Clin Nutr 68(1):126–133

Jeppesen PB, Hoy CE, Mortensen PB (1999) Differences in essential fatty acid requirements by enteral and parenteral routes of administration in patients with fat malabsorption. Am J Clin Nutr 70(1):78–84

Jeppesen PB, Christensen MS, Hoy CE, Mortensen PB (1997) Essential fatty acid deficiency in patients with severe fat malabsorption. Am J Clin Nutr 65(3):837–843

Kellenberger TA, Johnson TA, Zaske DE (1979) Essential fatty acid deficiency: a consequence of fat-free total parenteral nutrition. Am J Hosp Pharm 36(2):230–233

Kennedy DO, Jackson PA, Elliott JM, Scholey AB, Robertson BC, Greer J, Tiplady B, Buchanan T, Haskell CF (2009) Cognitive and mood effects of 8 weeks' supplementation with 400 mg or 1000 mg of the omega-3 essential fatty acid docosahexaenoic acid (DHA) in healthy children aged 10-12 years. Nutr Neurosci 12(2):48–56

Kishan AU, Modjtahedi BS, Martins EN, Modjtahedi SP, Morse LS (2011) Lipids and age-related macular degeneration. Surv Ophthalmol 56(3):195–213

Koletzko B, Cunnane S (1988) Human alpha-linolenic acid deficiency. Am J Clin Nutr 47(6):1084–1087

Kong XR (1981) Deficiency of essential fatty acid. Zhonghua Yi Xue Za Zhi 61(8):500–502

Landon C, Kerner JA, Castillo R, Adams L, Whalen R, Lewiston NJ (1981) Oral correction of essential fatty acid deficiency in cystic fibrosis. J Parenter Enteral Nutr 5(6):501–504

Le HD, Meisel JA, de Meijer VE, Gura KM, Puder M (2009) The essentiality of arachidonic acid and docosahexaenoic acid. Prostaglandins Leukot Essent Fatty Acids 81(2-3):165–170

Lee EJ, Simmer K, Gibson RA (1993) Essential fatty acid deficiency in parenterally fed preterm infants. J Paediatr Child Health 29(1):51–55

Levy J, DeFelice A, Lepage G (1990) Essential fatty acid deficiency mimicking porphyria cutanea tarda in a patient with chronic cholestasis. J Pediatr Gastroenterol Nutr 10(2):242–245

Martin PG, Valero Zanuy MA, Llorente AA, Acevedo Rodriguez MT (1990) Essential fatty acid deficiency in enteral nutrition. Nutr Hosp 5(2):123–125

Martinez M, Vazquez E (1998) MRI evidence that docosahexaenoic acid ethyl ester improves myelination in generalized peroxisomal disorders. Neurology 51(1):26–32

Mascioli EA, Lopes SM, Champagne C, Driscoll DF (1996) Essential fatty acid deficiency and home total parenteral nutrition patients. Nutrition 12(4):245–249

Mascioli EA, Smith MF, Trerice MS, Meng HC, Blackburn GL (1979) Effect of total parenteral nutrition with cycling on essential fatty acid deficiency. JPEN J Parenter Enteral Nutr 3(3):171–173

McCarthy DM, May RJ, Maher M, Brennan MF (1978) Trace metal and essential fatty acid deficiency during total parenteral nutrition. Am J Dig Dis 23(11):1009–1016

Meldrum DR, Dhopeshwarkar GA, Lin S, Smith ML (1976) Essential fatty acid deficiency with long-term hyperalimentation. Gynecol Oncol 4(1):66–69

Meng HC (1983) A case of human linolenic acid deficiency involving neurological abnormalities. Am J Clin Nutr 37(1):157–160

Meyer BJ, Mann NJ, Lewis JL, Milligan GC, Sinclair AJ, Howe PR (2003) Dietary intakes and food sources of omega-6 and omega-3 polyunsaturated fatty acids. Lipids 38(4):391–398

Mischler EH, Parrell SW, Farrell PM, Raynor WJ, Lemen RJ (1986) Correction of linoleic acid deficiency in cystic fibrosis. Pediatric research 20:36–41

NHMRC and NZ MoH (2006) Nutrient reference values for Australia and New Zealand including recommended dietary intakes. National Health and Medical Research Council, Canberra, Australia

O'Neill JA Jr, Caldwell MD, and Meng HC (1977) Essential fatty acid deficiency in surgical patients. Ann.Surg. 185(5), p. 535-542

Paassilta M, Kuusela E, Korppi M, Lemponen R, Kaila M, Nikkari ST (2014) Food allergy in small children carries a risk of essential fatty acid deficiency, as detected by elevated serum mead acid proportion of total fatty acids. Lipids Health Dis 13:180

Panteliadis C (1977) Studies on linoleic acid requirements in premature- and newborn infants under the conditions of parenteral feeding. Monatsschr Kinderheilkd 125(5):582–583

Parsons HG, O'Loughlin EV, Forbes D, Cooper D, Gall DG (1988) Supplemental calories improve essential fatty acid deficiency in cystic fibrosis patients. Pediatr Res 24(3):353–356

Paulsrud JR, Pensler L, Whitten CF, Stewart S, Holman RT (1972) Essential fatty acid deficiency in infants induced by fat-free intravenous feeding. Am J Clin Nutr 25(9):897–904

Peck LW, Monsen ER, Ahmad S (1996) Effect of three sources of long-chain fatty acids on the plasma fatty acid profile, plasma prostaglandin E2 concentrations, and pruritus symptoms in hemodialysis patients. Am J Clin Nutr 64(2):210–214

Petrovic D, Veljkovic S, Jevtic S (1964) The costrumogenic effect of deficiency in essential fatty acids in children. Ann Paediatr 203:59–67

Pettei MJ, Daftary S, Levine JJ (1991) Essential fatty acid deficiency associated with the use of a medium-chain-triglyceride infant formula in pediatric hepatobiliary disease. Am J Clin Nutr 53(5):1217–1221

Piper CM, Carroll PB, Dunn FL (1986) Diet-induced essential fatty acid deficiency in ambulatory patient with type I diabetes mellitus. Diabetes Care 9(3):291–293

Politi P, Cena H, Comelli M, Marrone G, Allegri C, Emanuele E, Ucelli di NS (2008) Behavioral effects of omega-3 fatty acid supplementation in young adults with severe autism: an open label study. Arch Med Res 39(7):682–685

Postuma R, Pease PW, Watts R, Taylor S, McEvoy FA (1978) Essential fatty acid deficiency in infants receiving parenteral nutrition. J Pediatr Surg 13(4):393–398

Press M, Kikuchi H, Shimoyama T, Thompson GR (1974) Diagnosis and treatment of essential fatty acid deficiency in man. Br Med J 2(5913):247–250

Presser SE, Bland H, Ziboh VA (1983) Essential fatty acid deficiency after intestinal bypass. J Am Acad Dermatol 8(1):127–128

Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Van DC, Galvin JE, Emond J, Jack CR, Jr., Weiner M, Shinto L, Aisen PS (2010) Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA 304(17):1903–1911

Rapoport SI, Ramadan E, Basselin M (2011) Docosahexaenoic acid (DHA) incorporation into the brain from plasma, as an in vivo biomarker of brain DHA metabolism and neurotransmission. Prostaglandins Other Lipid Mediat 96(1-4):109–113

Richardson TJ, Sgoutas D (1975) Essential fatty acid deficiency in four adult patients during total parenteral nutrition. Am J Clin Nutr 28(3):258–263

Riella MC, Broviac JW, Wells M, Scribner BH (1975) Essential fatty acid deficiency in human adults during total parenteral nutrition. Ann Intern Med 83(6):786–789

Roongpisuthipong W, Phanachet P, Roongpisuthipong C, Rajatanavin N (2012) Essential fatty acid deficiency while a patient receiving fat regimen total parenteral nutrition. BMJ Case Rep 2012

Ruiz JI, Aldamiz-Echevarria L, Arrizabalaga J, Aquino L, Jimeno P, Perez-Nanclares G, Sanjurjo P (2001) Polyunsaturated fatty acid deficiency during dietary treatment of very long chain acyl-CoA dehydrogenase deficiency. Rescue with soybean oil. J Inherit Metab Dis 24:493–503

Ryan AS, Nelson EB (2008) Assessing the effect of docosahexaenoic acid on cognitive functions in healthy, preschool children: a randomized, placebo-controlled, double-blind study. Clin Pediatr (Phila) 47(4):355–362

Sacks GS, Brown RO, Collier P, Kudsk KA (1994) Failure of topical vegetable oils to prevent essential fatty acid deficiency in a critically ill patient receiving long-term parenteral nutrition. JPEN J Parenter Enteral Nutr 18(3):274–277

Salem N, Jr., Litman B, Kim HY, Gawrisch K (2001) Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids 36(9):945–959

SanGiovanni JP, Chew EY (2005) The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. Prog Retin Eye Res 24(1):87–138

Siguel EN, Blumberg JB, Caesar J (1986) Monitoring the optimal infusion of intravenous lipids. Detection of essential fatty acid deficiency. Arch Pathol Lab Med 110(9):792–797

Siguel EN, Chee KM, Gong JX, Schaefer EJ (1987) Criteria for essential fatty acid deficiency in plasma as assessed by capillary column gas-liquid chromatography. Clin Chem 33(10):1869–1873

Socha P, Koletzko B, Swiatowska A, Pawlowska J, Stolarczyk A, Socha J (1998) Essential fatty acid metabolism in infants with cholestasis. Acta Paediatr 87:278–283

Socha P, Ryzko J, Koletzko B, Celinska-Cedro D, Woynarowski M, Czubkowski P, Socha J (2005) Essential fatty acid depletion in children with inflammatory bowel disease. Scand J Gastroenterol 40:573–577

Srigley CT, Rader JI (2014) Content and composition of fatty acids in marine oil omega-3 supplements. J Agric Food Chem 62(29):7268–7278

Stein TP, Buzby GP, Hargrove WC, III Leskiw MJ, and Mullen JL (1980) Essential fatty acid deficiency in patients receiving simultaneous parenteral and oral nutrition. J Parenter Enteral Nutr 4(4):343-345

Stein TP, Marino PL, Harner RN, Schluter MD, Leskiw MJ, Black S (1983) Linoleate and possibly linolenate deficiency in a patient on long-term intravenous nutrition at home. J Am Coll Nutr 2(3):241–247

Steinkamp G, Demmelmair H, Ruhl-Bagheri I, von der HH, Koletzko B (2000) Energy supplements rich in linoleic acid improve body weight and essential fatty acid status of cystic fibrosis patients. J Pediatr Gastroenterol Nutr 31(4):418–423

Stough C, Downey L, Silber B, Lloyd J, Kure C, Wesnes K, Camfield D (2012) The effects of 90-day supplementation with the omega-3 essential fatty acid docosahexaenoic acid (DHA) on cognitive function and visual acuity in a healthy aging population. Neurobiol Aging 33(4):824–3

Strandvik B, Berg U, Kallner A, Kusoffsky E (1989) Effect on renal function of essential fatty acid supplementation in cystic fibrosis. J Pediatr 115(2):242–250

Sun H, Como PG, Downey LC, Murphy D, Ariagno RL, Rodriguez W (2015) Infant formula and neurocognitive outcomes: impact of study end-point selection. J Perinatol 35(10):867–874

Tanphaichitr V, Tanchurat N, Viriyapanich T, Komindr S (1979) Essential fatty acid status in Thai patients receiving total parenteral nutrition. JPEN J Parenter Enteral Nutr 3(3):164–168

Uauy RD, Birch DG, Birch EE, Tyson JE, Hoffman DR (1990) Effect of dietary omega-3 fatty acids on retinal function of very-low-birth-weight neonates. Pediatr Res 28(5):485–492

University of Otago and Ministry of Health (2011) A focus on nutrition: key findings of the 2008/09 New Zealand Adult Nutrition Survey. Ministry of Health Wellington, New Zealand,

van Egmond AW, Kosorok MR, Koscik R, Laxova A, Farrell PM (1996) Effect of linoleic acid intake on growth of infants with cystic fibrosis. Am J Clin Nutr 63:746–752

von Chwalibogowski A (1937) Experimentaluntersuchungen uber kalorisch ausreichende, qualitativ einseitage Ernahrung des Sauglings. Acta Paediatr 22:110-123

Warwick WJ, Holman RT, Quie PG, Good RA (1959) Chylous ascites and lymphedema. AMA J Dis Child 98:317–329

Wene JD, Connor WE, DenBesten L (1975) The development of essential fatty acid deficiency in healthy men fed fat-free diets intravenously and orally. J Clin Invest 56(1):127–134

Wurtman RJ, Cansev M, Ulus IH (2009) Synapse formation is enhanced by oral administration of uridine and DHA, the circulating precursors of brain phosphatides. J Nutr Health Aging 13(3):189–197

Yamanaka WK, Clemans GW, Hutchinson ML (1981) Essential fatty acids deficiency in humans. Prog Lipid Res 19(3-4):187–215

Yoshimoto FK, Yoshimoto K, Tanaka T, Saima S, Kikuchi Y, Shay J, Horrobin DF, Echizen H (1999) Effects of oral supplementation with evening primrose oil for six weeks on plasma essential fatty acids and uremic skin symptoms in hemodialysis patients. Nephron 81:151–159

# Appendix 1: Search terms

The following search terms were used to identify studies for including in the review:

**Medline – PubMed portal**

Searched 4 March 2015 using the following MeSH terms:

((("fatty acids, essential/administration and dosage"[MeSH Terms])) OR "fatty acids, essential/deficiency"[MeSH Terms]) OR "fatty acids, essential/therapy"[MeSH Terms]

Limited to: Species: Human

No date limits applied.

(Retrieved 1785 results)

**Cochrane Library (Central)**

Searched 3 March 2015 for:

"Essential fatty acid" in Title, Abstract, Keywords and "docosahexaenoic acid" in Title, Abstract, Keywords and "deficiency" in Title, Abstract, Keywords , No limits applied.

(Retrieved 14 results)

**Embase®**

Searched 10 March 2015 for:

1. 'essential fatty acid' AND [humans]/lim (Retrieved 3152 results)

2. 'essential fatty acid' AND 'docosahexanoic acid' AND [humans]/lim

(Retrieved 18 results)

3. 'essential fatty acid' AND 'docosahexanoic acid' AND deficiency AND [humans]/lim

(Retrieved 8 results)

# Appendix 2: Studies excluded at full text review

|  | Study ID | Reason for Exclusion |
| --- | --- | --- |
|  | (Anon 1959) | Review article without new studies. |
|  | (Anon 1985) | Review article without new studies. |
|  | (Anon 1986) | Review article without new studies. |
|  | (Ballabriga and Martinez 1976) | Biochemical assessment of EFAD only, which is not specific to DHA. No reported clinical changes associated with EFAD |
|  | (Barr et al. 1981) | Biochemical assessment of EFAD only, which is not specific to DHA. No clinical changes associated with these biochemical changes were reported. |
|  | (Berg et al. 1976) | Cronkhite-Canada Syndrome patient. PN fatty acid intervention but not clear if it contained DHA or not. |
|  | (Bistrian et al. 1981) | Although this study described clinical changes the authors attributed to EFAD, it did not include a phase where lipid was reintroduced to enteral or parenteral therapy to address these reported clinical changes. Treatment of the patient included topical application of oils. |
|  | (Bjerve 1985) | Language translation not available (Norwegian). Cases reported likely to have been included in other English language reports in this series by the same authors. |
|  | (Bjerve 1989) | Brain-damaged bedridden patient received lipid containing DHA with other EFA as oil. Brain or vision functions were not assessed. |
|  | (Bjerve et al. 1986) | Language translation not available (Norwegian). Cases reported likely to have been included in other English language reports in this series by the same authors. |
|  | (Bjerve et al. 1987b) | Bedridden tube-fed patient. Enternal fatty acid intervention did not include DHA. |
|  | (Bjerve et al. 1987a) | Bedridden brain-damaged patients received lipid containing DHA with other EFA as oil through gastric tube. Brain or vision functions were not assessed. |
|  | (Bjerve et al. 1987c) | Bedridden and tube-fed patient. Enternal lipid intervention without DHA. |
|  | (Bjerve et al. 1988) | Tube-fed patient with genetic disorder received DHA with other EFA as intervention. However, brain or vision functions were not assessed.  |
|  | (Bjerve et al. 1989) | Bedridden brain-damaged patients received lipid containing DHA with other EFA as oil through gastric tube. Brain or vision functions were not assessed. |
|  | (Bozian and Moussavian 1982) | Letter to the journal editor commenting on another study. Does not include any new case studies. |
|  | (Bozian and Piepmeyer 1976) | Letter to the journal editor commenting on another study. Does not include any new case studies. |
|  | (Brown WR et al. 1937) | Study did not include a phase where lipid was reintroduced to therapy to address reported clinical changes |
|  | (Burney et al. 1979) | Seriously ill infant (3 weeks old) patient. Not clear if the PN dietary intervention included DHA. Brain and vision functions were not assessed. |
|  | (Caldwell et al. 1972) | Seriously ill infant (6 months old) patient. Brain and vision functions not assessed. Intralipid intervention did not include DHA. |
|  | (Cederholm et al. 1994) | Participants were not on a lipid-free background diet, although were malnourished due to disease. The only clinical changes assessed were for delayed cutaneous hypersensitivity |
|  | (Chase et al. 1979) | Participants were not on a lipid-free background diet |
|  | (Collins and Connelly 1965) | Biochemical assessment of EFAD only with no clinical data. Not relevant to DHA. |
|  | (Collins et al. 1971) | Chronic patient. Intralipid intervention did not include DHA. |
|  | (Darmstadt et al. 2000) | Chronically-ill patients with signs of EFAD, not relevant to DHA. Dietary intervention does not appear to be exclusively lipid. No brain or vision functions were assessed. |
|  | (de Meijer et al. 2009) | Letter to the editor, does not contain new case study data suitable for assessment. |
|  | (de Meijer et al. 2010) | Study did not include a phase where participants received a lipid free diet. All patients were either maintained on PN with fish oil added or switched from PN with soy oil. |
|  | (Dodge et al. 1975) | Chronically-ill infant (3 days old). Parenteral intralipid intervention did not include DHA and no assessment for brain or vision reported. |
|  | (Duerksen and McCurdy 2005) | Severely malnourished anorexic patient. Intralipid intervention did not include DHA. |
|  | (Esteve-Comas and Gassull 2001) | Letter to the editor, does not contain new case study data suitable for assessment |
|  | (Faintuch et al. 1976) | The same cases as later reported in Faintuch et al. 1977 |
|  | (Faintuch et al. 1977) | Malnourished, GI surgery patient. Dietary fatty acid intervention but did not include DHA. |
|  | (Fleming et al. 1976a) | Chronically ill patients. Lipid dietary intervention did not include DHA. No assessment for brain or vision functions. |
|  | (Fleming et al. 1976b) | Lipid dietary intervention did not include DHA. No assessment for brain or vision functions. |
|  | (Freund et al. 1979) | Chronic patients. Intralipid intervention with PN fatty acid intervention but did not include DHA.  |
|  | (Friedman et al. 1976) | Biochemical assessment of EFAD only which is not specific to DHA. No reported clinical changes associated with EFAD. Participants were not given lipid therapy (blood transfusions were provided). |
|  | (Goodgame et al. 1978) | Cancer patient with signs of essential fatty acid deficiency. Intralipid intervention with PN fatty acid intervention but did not include DHA. |
|  | (Gröer 1919) | Study did not include a phase where lipid was reintroduced to therapy to address reported clinical changes |
|  | (Gura et al. 2005) | Chronically-ill patient receiving fish oil capsules containing DHA and other EFA. Brain or vision functions were not assessed. |
|  | (Hansen and Wiese 1954) | Study examined serum plasma only and did not assess clinical changes or effects of supplying additional lipids |
|  | (Hansen et al. 1958) | Infants (up to 12 months old). Dietary fatty acid intervention but did not include DHA. |
|  | (Hansen et al. 1963) | Full term infants (up to 12 months old). Dietary fatty acid intervention but did not include DHA. |
|  | (Heymans et al. 1982) | Chronically-ill patient receiving intralipid intervention with PN fatty acid intervention but did not include DHA. Brain and vision functions were not assessed. |
|  | (Hirono et al. 1977) | Seriously ill infant (2-5 months old) patients. Intralipid intervention did not include DHA. Brain and vision functions not assessed. |
|  | (Holman et al. 1982) | Seriously-ill patient on PN intervention but did not include DHA. |
|  | (Hurgoiu et al. 1986) | Premature infants. Language translation not available (Romanian). |
|  | (Igarashi et al. 1989) | Chronically-ill patients (1-month old infant and a 12-year old child) on PN that did not clearly include DHA. Brain or vision functions were not assessed. |
|  | (James and Lovelock 1958) | Review article without new studies. |
|  | (Jeejeebhoy et al. 1973) | Chronically-ill patient. Intralipid intervention did not include DHA. |
|  | (Jeppesen et al. 1997) | Study did not include a phase where lipid or DHA were reintroduced to therapy to address reported clinical changes |
|  | (Jeppesen et al. 1998) | Study did not include a phase where lipid or DHA were reintroduced to therapy to address reported clinical changes |
|  | (Jeppesen et al. 1999) | Biochemical assessment of EFAD only. Not specific to DHA and no reported clinical changes. |
|  | (Kellenberger et al. 1979) | Chronically-ill patient on PN intralipid intervention without DHA. Brain and vision functions not assessed. |
|  | (Koletzko and Cunnane 1988) | Letter without new studies. |
|  | (Kong 1981) | Review article without new studies. |
|  | (Landon et al. 1981) | Background diet not lipid free. No DHA intervention. |
|  | (Le et al. 2009) | Biochemical assessment of essential fatty acid deficiency (EFAD) only; no reported clinical changes associated with EFAD |
|  | (Lee et al. 1993) | Intralipid intervention with PN fatty acid intervention but did not include DHA. |
|  | (Levy et al. 1990) | Seriously-ill patient on intralipid intervention without DHA. Brain and vision functions not assessed. |
|  | (Martin et al. 1990) | Case study that did not include DHA intervention or assessment for brain or vision functions. |
|  | (Mascioli et al. 1979) | Biochemical assessment of EFAD only which is not specific to DHA. No clinical changes reported. |
|  | (Mascioli et al. 1996) | Biochemical assessment of EFAD only which is not specific to DHA. No clinical changes reported. |
|  | (McCarthy et al. 1978) | Chronically-ill patient on PN intralipid intervention without DHA. Brain and vision functions not assessed. |
|  | (Meldrum et al. 1976) | Biochemical assessment of essential fatty acid deficiency (EFAD) only; no reported clinical changes associated with EFAD |
|  | (Meng 1983) | Review article without new studies |
|  | (Mischler et al. 1986) | No DHA intervention. Did not report on clinical changes in participants and did not assesse brain or vision functions. |
|  | (O'Neill JA Jr et al. 1977) | Chronically-ill patients after surgeries. Mixture of intralipid intervention and PN fatty acid intervention but did not include DHA. |
|  | (Paassilta et al. 2014) | Study did not include a phase where lipid was reintroduced to therapy to assess reported clinical changes |
|  | (Panteliadis 1977) | Did not report clinical changes, brain or vision functions assessment in participants |
|  | (Parsons et al. 1988) | Did not report clinical changes, brain or vision functions assessment in participants |
|  | (Paulsrud et al. 1972) | Biochemical assessment of EFAD only which is not specific to DHA. No reported clinical changes associated with EFAD |
|  | (Peck et al. 1996) | Biochemical assessment of EFAD only which is not specific to DHA. No reported clinical changes associated with EFAD |
|  | (Petrovic et al. 1964) | Study did not include a phase where lipid was reintroduced to therapy to address reported clinical changes |
|  | (Pettei et al. 1991) | Seriously-ill infant (1.5-2 months old) patients on intralipid intervention without DHA. Brain and vision functions not assessed. |
|  | (Piper et al. 1986) | Dietary lipid intervention did not include DHA. Vision function was not assessed.  |
|  | (Postuma et al. 1978) | Seriously-ill preterm infant (2-8 days) patients on intralipid intervention without DHA. Brain and vision functions were not assessed. |
|  | (Press et al. 1974) | Seriously-ill patient on intralipid intervention without DHA. Brain and vision functions not assessed. |
|  | (Presser et al. 1983) | Study did not include a phase where lipid was reintroduced to therapy to address reported clinical changes |
|  | (Richardson and Sgoutas 1975) | Study did not include a phase where lipid was reintroduced to therapy to address reported clinical changes |
|  | (Riella et al. 1975) | Seriously-ill patient on intralipid PN intervention without DHA. Brain and vision functions not assessed. |
|  | (Roongpisuthipong et al. 2012) | Critically-ill patient on intralipid PN intervention without DHA. Brain and vision functions not assessed. |
|  | (Ruiz et al. 2001) | Biochemical assessment of EFAD only which is not specific to DHA. No reported clinical changes associated with EFAD |
|  | (Sacks et al. 1994) | Seriously-ill patient on intralipid PN intervention without DHA. Brain and vision functions not assessed. |
|  | (Siguel et al. 1986) | Study did not include a phase where lipid was reintroduced to therapy to address reported clinical changes. Biochemical assessment of EFAD only, which is not specific to DHA. No reported clinical changes associated with EFAD |
|  | (Siguel et al. 1987) | No dietary intervention from fat free diet to one containing added lipids. |
|  | (Socha et al. 1998) | Study did not include a phase where lipid was reintroduced to therapy to address reported clinical changes. Biochemical assessment of EFAD only, which is not specific to DHA. No reported clinical changes associated with EFAD |
|  | (Socha et al. 2005) | Biochemical assessment of essential fatty acid deficiency (EFAD) only; no dietary intervention with additional lipids. |
|  | (Stein et al. 1983) | Seriously-ill patient on intralipid PN intervention without DHA. |
|  | (Stein et al. 1980) | PN intervention did not include DHA. Did not report on clinical changes in participants. |
|  | (Steinkamp et al. 2000) | Chronically-ill patients with lipid intervention not containing DHA. |
|  | (Strandvik et al. 1989) | Did not report on clinical changes in participants |
|  | (Tanphaichitr et al. 1979) | Study did not include a phase where DHA alone was reintroduced to therapy to address reported clinical changes. Therapy to treat deficiency was enteral feeds (undefined) or normal diet. |
|  | (van Egmond et al. 1996) | Chronically-ill infants and early children (1.5 to 15 months old). Background diet was not lipid free; study compared pre-digested formula with two different LA levels.  |
|  | (von Chwalibogowski 1937) | Study did not include a phase where lipid was reintroduced to therapy to address reported clinical changes |
|  | (Warwick et al. 1959) | Seriously-ill patient on lipid intervention without DHA. |
|  | (Wene et al. 1975) | Biochemical assessment of EFAD only, which is not specific to DHA. No reported clinical changes associated with EFAD |
|  | (Yamanaka et al. 1981) | Review article without new case studies |
|  | (Yoshimoto et al. 1999) | Biochemical assessment of EFAD only, which is not specific to DHA. No reported clinical changes associated with EFAD |

EFAD: essential fatty acid deficiency. PN: parenteral nutrition.

# Appendix 3: GRADE summary of findings tables

Question: ***Is dietary intake of docosahexaenoic acid (DHA) required to maintain normal brain and vision function?***

|  |  |  |  |
| --- | --- | --- | --- |
| **Quality assessment of body of evidence** | **Participant numbers** | **Mean effect size** | **Quality (degree of certainty)** |
| **Number of studies** | **Design** | **Risk of bias** | **Inconsistency** | **Indirectness** | **Imprecision** | **Considerations** |
| **All symptoms potentially related to normal brain function** |
| 0 | n/a | n/a | n/a | n/a | n/a |  | 0 | Not estimated | Non-assessable |
| **All symptoms potentially related to normal vision** |
| 0 | n/a | n/a | n/a | n/a | n/a |  | 0 | Not estimated | Non-assessable |